Lite Strategy, Inc.

Lite Strategy, Inc.

Overview

• Sector: Pharmaceutical/biotech with a digital-asset treasury component
• Core focus: Development of novel cancer therapies; expanding pre-clinical development into non-oncologic indications
• Treasury strategy: Holds Litecoin (LTC) as a primary reserve asset and conducts digital asset treasury management, including writing covered call options on LTC to generate liquidity and income while maintaining exposure to LTC
• Headquarters/operations: United States; five employees as of June 30, 2026

Drug development and pipeline

• Primary programs:
  • Voruciclib — oral CDK9 inhibitor; originally developed for AML and B‑cell malignancies; acquired from Presage with exclusive worldwide rights
  • Zandelisib — oral PI3Kδ inhibitor; acquired from Pathway Therapeutics with exclusive worldwide rights
  • ME-344 — intravenous mitochondrial inhibitor (oxidative phosphorylation); sold to Aardvark Therapeutics in October 2024 for obesity/metabolic indications, with potential future milestone payments up to $62.0 million
• Current status:
  • Voruciclib and zandelisib remain in the pipeline. Voruciclib is being evaluated in pre-clinical non-oncologic indications; non-oncologic preclinical activities for voruciclib began in fiscal year 2026
  • The company is pursuing strategic alternatives for its assets, including potential out-licensing or sales

Intellectual property

• Voruciclib: U.S. patent protection (one U.S. patent covering a crystal form; projected expiry 2042) plus multiple foreign patents; portfolio includes related formulations and methods of use
• Zandelisib: U.S. patents covering composition of matter, formulations, and methods of use; multiple foreign patents; U.S. patent expiries projected in 2030–2032 (subject to extensions)

Competitive landscape

• Operates in a highly competitive oncology drug-development environment, where larger peers often have greater resources

Financing, transactions, and capital structure

• PIPE financing:
  • July 22, 2025: Closed a $100.0 million PIPE
  • Securities issued: 23,216,898 shares of common stock at $3.42 per share; 6,022,869 pre-funded warrants
  • Advisory warrants: up to 3,070,177 shares at a weighted-average exercise price of $4.10 per share
• Share repurchase program:
  • Board authorized up to $25.0 million for share repurchases (effective October 29, 2025)
  • As of June 30, 2026, repurchased 4,378,525 shares at a weighted-average price of $1.12 per share
  • Approximately $20.2 million remained available under the program as of June 30, 2026
  • Repurchased shares are held in treasury and then returned to authorized but unissued status
• Treasury/LTC strategy:
  • Acquisition of LTC tokens was funded by PIPE proceeds
  • Contracts with GSR Markets Ltd. to write covered call options on LTC holdings to generate incremental liquidity and income while retaining exposure to LTC
  • Risks include LTC price volatility and the potential for delivery of LTC to option counterparties if options are exercised
• Outstanding equity instruments:
  • Common stock warrants: 3,406,839 shares; weighted-average exercise price $3.90; expirations between October 2027 and July 22, 2030
  • Pre-funded warrants: 546,348 (exercise price $0.0001; exercisable until fully exercised)
  • Employee/management stock options: 1,731,085 shares underlying options
• Cash and liquidity outlook:
  • The company reports unrestricted cash and unrestricted digital assets sufficient to fund currently planned operations for at least the next 12 months and discloses ongoing losses that could require additional funding

Financial performance (selected highlights)

• Net loss:
  • Fiscal year ended June 30, 2026: $71.2 million
  • Fiscal year ended June 30, 2025: $15.9 million
• Accumulated deficit: $475.3 million as of June 30, 2026
• Dividends: The company has not paid cash dividends and does not anticipate paying cash dividends in the foreseeable future
• Other financial considerations:
  • LTC holdings are volatile and LTC price movements can affect financial results
  • ME-344 sale included potential milestone payments up to $62.0 million, contingent on development and commercialization targets

Operations and corporate

• Manufacturing: No owned manufacturing facilities; relies on contract manufacturers for pre-clinical development, clinical trials, and potential commercial-scale manufacturing; manufacturing must comply with cGMP standards
• Corporate governance and locations:
  • Five employees as of June 30, 2026; CEO and CFO have prior pharma/biotech experience
  • Board and management oversight includes cybersecurity and risk management components
  • The company is pursuing strategic alternatives, licensing opportunities, and collaborations as part of its long-term plan
• Public filings and investor information: Annual and interim reports filed with the SEC; investor materials available on the company website (litestrategy.com) and SEC EDGAR

Regulatory and IP landscape

• U.S. regulatory pathway: IND submission, clinical trials (Phases 1–3), FDA review (NDA), and potential accelerated or breakthrough designations; post-approval obligations include pharmacovigilance and manufacturing compliance
• EU/UK regulatory framework: Centralized or decentralized procedures in the EU; post-Brexit UK framework under the MHRA; clinical trials in the EU conducted under the Clinical Trials Regulation with a single submission through CTIS
• Patent protection: Patent term expiries in the 2030s–2040s for portfolio assets, with possible extensions; the company’s programs depend on patent enforcement, licensing, and defense against third-party challenges

Summary

Lite Strategy, Inc. is a clinical-stage pharmaceutical company focused on cancer therapies (voruciclib and zandelisib) and advancing preclinical non-oncologic programs. The company combines traditional drug-development activities with a Litecoin-based treasury strategy to generate liquidity and income. It operates with a small workforce, relies on contract manufacturers, reports material net losses and an accumulated deficit, and is pursuing partnerships, licensing opportunities, and potential monetization of its LTC position.